Precise Tumor Molecular Profile Test News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The company reported revenues of $164.9 million, all of which came from its molecular testing business, beating analysts' consensus expectation.

Paul diazMychoice cdxBracanalysis cdxPrecise oncology solutionsMyriad geneticsWall streetSalt lake city basedTrusight oncologySalt lake city based intermountainMyrisk hereditary cancer testPrecise tumor molecular profile test